跳至主要内容
临床试验/CTRI/2019/12/022521
CTRI/2019/12/022521已完成未知

Homoeopathic drug proving: Randomized double-blind placebo-controlled trial of PRO1 - Nil

ife Force Foundation Trust0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Healthy individuals with no apparent disease and normal routine laboratory parameters during screening
  • 2.Intelligent enough to record carefully the facts, subjective and objective symptoms generated by the drug during proving.
  • 3.Able to be informed of the nature of the study and willing to give written informed consent

排除标准

  • 1.Any disease or condition which might compromise the hematopoietic, renal, endocrine, pulmonary, central nervous system, cardiovascular, immunological, dermatological, gastro-intestinal or any other body system
  • 2.Persons with colour blindness.
  • 3.Persons who have undergone surgery in last two months.
  • 4.Planned medical / dental treatment during the proving period including herbal or dietary supplements, procedures, or medications that are likely to interfere with, or substantially alter, responsiveness to the proving substance.
  • 5.Volunteers on regular medication (allopathic, ayurvedic, homoeopathic, naturopathic, unani, etc.) for any acute or chronic disease.
  • 6.Participant must not be on any homoeopathic remedy in the preceding one month and have had no significant change in health status in last one month.
  • 7.Emotionally disturbed, hysterical or anxious persons.
  • 8.Persons having known history of allergies, food hypersensitivity, etc.
  • 9.Women during pregnancy, puerperium and while breast-feeding.
  • 10.Smokers who smoke more than 10 cigarettes per day
  • 11.Recent history of alcoholism / drug addictions or unlikely to refrain from excessive alcohol consumption / drug intake during the study period
  • 12.Participation in another clinical or proving trial during the last 6 months

研究者

发起方
ife Force Foundation Trust

相似试验

Study to observe clinical symptoms of PRO1 in... | 临床试验